Views & Analysis Searching for new hope in Alzheimer’s For the best part of two decades, it seemed as if pharma hit a brick wall as it tried to find new treatments for Alzheimer’s.
R&D Citing phase 2 figures, Axon looks for big pharma investment... After trial failure upon trial failure in Alzheimer's disease will big pharma be prepared to fund a trial using a new approach instead of the amyloid-targeting drugs, that have caused so mu
Oncology LSX2026: Addressing adult eye cancer, with Roi Raz Roi Raz, CEO of ReBio Pharma, discusses injectable, bioresorbable sustained release delivery for ophthalmic therapeutics at LSX 2026.
Sales & Marketing Sponsored Using AI-driven synthetic personas to take your insights fur... As AI continues to reshape the healthcare landscape, pharma teams are beginning to leverage synthetic personas.
